Live Webinar

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Hosted by AJMC, Managed Healthcare Executive, Pharmacy Times and PBMI

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
  • News
  • Watch
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe
|Articles|October 10, 2011

Supplements and Featured Publications

  • The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disea
  • Volume 17
  • Issue 12 Suppl

The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disease

After reading "The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson’s Disease,” participants must complete the online evaluation form and achieve a passing score of 70% or higher on the online posttest. Upon submission of the completed evaluation and posttest, participants may print their statement of credit.

TAKE PHYSICIAN CME TEST

TAKE PHARMACIST CE TEST

Download PDF: The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disease

Articles in this issue

almost 15 years ago

Implications for Managed Care for Improving Outcomes in Parkinson's Disease: Balancing Aggressive Treatment With Appropriate Care

almost 15 years ago

Advanced Strategies for Treatment of Parkinson's Disease: The Role of Early Treatment

almost 15 years ago

The Impact and Management of Nonmotor Symptoms of Parkinson's Disease

almost 15 years ago

Participating Faculty: The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disease

Related Content